TBC1D9 Inhibitors
TBC1D9 inhibitors belong to a distinctive class of chemical compounds that specifically target the TBC1D9 family of proteins, which are involved in cellular signaling and intracellular trafficking processes. TBC1D9, also known as Tre-2/Bub2/Cdc16 (TBC) domain family member 9, is a protein with a conserved TBC domain, implicated in the regulation of small GTPases, such as Rab proteins. The TBC domain functions as a GTPase-activating protein (GAP), playing a crucial role in modulating the activity of these GTPases by facilitating the hydrolysis of GTP to GDP. By inhibiting TBC1D9, the inhibitors disrupt the finely tuned balance of GTPase activity, leading to altered cellular dynamics.
TBC1D9 inhibitors involves molecular components that interact with key regions of the TBC domain, preventing its engagement with the target GTPase. This interference can result in dysregulated intracellular vesicle trafficking, perturbed endosomal pathways, and impaired cellular responses to external signals. Researchers aim to understand the precise mechanisms by which TBC1D9 inhibitors exert their effects, shedding light on the intricate interplay of molecular events governing cellular homeostasis. As a promising area of study in chemical biology, the development of TBC1D9 inhibitors holds potential for elucidating fundamental cellular processes and expanding our knowledge of the intricate signaling networks within cells.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A PI3K inhibitor that can alter insulin signaling, a pathway where TBC1D9 might be involved. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Another PI3K inhibitor, it affects insulin signaling and could, therefore, influence TBC1D9's regulatory activities. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An MEK inhibitor, affects insulin signaling and vesicle trafficking by altering the MAPK/ERK pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Inhibits mTOR, a central player in cell growth and metabolism, potentially affecting TBC1D9's associated pathways. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Targets autophagy by inhibiting ubiquitin-specific peptidases, indirectly influencing vesicle trafficking. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts protein transport by inhibiting the exchange of protein and other molecules across the Golgi apparatus. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
An ionophore that disrupts Golgi function and can indirectly influence vesicle trafficking pathways. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
A GTPase inhibitor that can interfere with vesicle formation and trafficking, processes potentially affected by TBC1D9. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $79.00 | 2 | |
An AMPK activator that influences cellular metabolism and insulin signaling, affecting TBC1D9's activity domains. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Activates PPARα, influencing lipid metabolism and indirectly affecting insulin signaling pathways. | ||||||